Santosh Kakad, AGM – Sales and Marketing, Nitika Pharmaceutical Specialties

Vadodara Pharma Summit 2024 | 25th October 2024 | Vadodara


In this video:
Santosh Kakad, AGM – Sales and Marketing, Nitika Pharmaceutical Specialties

Key Takeaway:
Nitrosamine levels in low-nitrite formulations remained under control even for high-risk products. Supplier selection of filler excipients, such as MCC and lactose, and the replacement of critical excipients, such as crospovidone, are obvious nitrosamine risk-mitigation strategies

Comments (0)
Add Comment